submit to the journals

ESMO Highlights

flipper_slider

Editor's Choice

Almost 60% of European countries do not recognise cancer nursing as a defined specialty, and therefore do not provide targeted educational programmes. This has resulted in vast differences in the education levels and...

ESMO Highlights Videos

In an expert interview at ESMO 2018, Dr András Illés discusses the current research behind RGB-02, a biosimilar pegfilgrastim for the treatment of chemotherapy-induced neutropenia. Biosimilars are subjected to rigorous clinical trials to ensure equivalence to the originator drug in terms of safety...
In this interview, filmed at ESMO 2018, Professor Schadendorf discusses the use of encorafenib plus binimetinib for BRAF-mutant metastatic melanoma. Questions: 1. Could you tell us a little about the efficacy and safety findings of the COLUMBUS study that have led to the recent European...
Dr Daniel A Vorobiof, ​Chief Medical Officer at Belong.Life, New York, NY, US, provides an overview of the findings of his study on the impact of cancer-related fatigue on patients and caregivers, and options of management and prevention.​ Belong.Life is the world’s largest professional social...
In this interview, filmed at ESMO 2018, Dr Do-Youn Oh highlights the importance of these results for biliary tract cancer, and where she thinks future research could lead. Questions: 1. What was the background and rationale behind the phase 1 study investigating M7824 in biliary tract cancer...
In this interview at ESMO 2018, Marc Peeters talks to touchONCOLOGY about colorectal cancer tumour location and biomarkers. He explains that left-sided cancers have a better prognosis and suggests some possible reasons for this. Dr Peeters also discusses how the use of biomarkers has developed in...
There is a lack of consistency regarding what constitutes as financial toxicity and how to measure it in patients who have cancer. At this year’s ESMO, we met up with Dr Eva Winkler to learn more about this under-researched topic. As patients with cancer live longer, their financial burden...
In this interview, at ESMO 2018, Dr Raffaele Califano talks to touchONCOLOGY about epidermal growth factor receptor (EGFR) expression in non-small cell lung cancer (NSCLC). He explains the importance of detecting EGFR activity prior to treatment in order to treat the patient effectively. Dr...
Elderly patients are often under-represented in clinical trials and therefore may not receive the necessary treatment. Dr Matti Aapro explains that elderly patients should receive immunotherapy under the same circumstances as younger patients. While they may experience more treatment-related...
M7824 is a bifunctional fusion protein which targets transforming growth factor-beta (TGF-beta) and programmed death-ligand 1 (PD-L1). This makes it suited to HPV-positive squamous cell carcinoma of the head and neck, as the TGS signalling pathway in this indication is frequently dysregulated. At...
The Poseidon study was a phase I/II study in second-line KRAS mild-type metastatic colorectal cancer (mCRC) that did not meet its endpoint of progression-free survival, but did suggest a subgroup of patients with high alpha v beta 6 integrin expression who would benefit from abituzumab. In this...
We met with Dr Paolo Ascierto at ESMO 2018 to discuss the recent developments in the treatment of advanced melanoma. In this interview with touchONCOLOGY, Dr Ascierto reviews some of the recent trials investigating various immunotherapy combinations, and how survival rates have increased over the...
The current standard of care for prostate cancer can sometimes cease to be effective, causing the cancer to worsen. The TRITON2 and TRITON3 studies are looking at the PARP inhibitor, rucaparib, in the treatment of prostate cancer with BRCA1 and BRCA2 mutations. In addition, the TRITON trials are...
Complete pathological response has been recognised as an important predictor of long-term remission, meaning it is often a key endpoint in clinical trials. Dr Bernardo Rapoport talks to touchONCOLOGY about complete pathological response and which clinical characteristics, such as molecular subtype...
Ricardo Alvarez, Medical Director of the Breast Cancer Center...
The European Oncology Nurses Society (EONS) is currently undertaking its RECaN project which is aimed at increasing the recognition of cancer nursing across Europe. At this year’s ESMO congress, EONS presented the first two phases of the RECaN project. Past President of EONS, Prof Daniel Kelly, is...